Sumit K. Subudhi, Ph.D. - Publications

Affiliations: 
2004 University of Chicago, Chicago, IL 
Area:
Immunology

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine. PMID 28346412 DOI: 10.1038/nm.4308  0.32
2016 Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 27698113 DOI: 10.1073/pnas.1611421113  0.6
2016 Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7: 12335. PMID 27498556 DOI: 10.1038/ncomms12335  0.6
2016 Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass.). 22: 117-20. PMID 27111907 DOI: 10.1097/PPO.0000000000000176  0.6
2014 Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/scitranslmed.3008095  0.6
2013 Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155: 1309-22. PMID 24315100 DOI: 10.1016/j.cell.2013.11.012  0.6
2013 Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, et al. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6112-25. PMID 24081977 DOI: 10.1158/1078-0432.CCR-12-3580  0.6
2012 Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet. Oncology. 13: 1105-13. PMID 23059047 DOI: 10.1016/S1470-2045(12)70263-2  0.6
2012 Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 217: 590-2. PMID 22459268 DOI: 10.1016/j.imbio.2011.11.001  0.6
2010 Subudhi SK, Callahan MK, Wolchok JD. Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park, N.Y.). 24: 1288, 1294. PMID 21294472  0.6
2005 Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. Journal of Immunology (Baltimore, Md. : 1950). 175: 1295-300. PMID 16002734 DOI: 10.4049/jimmunol.175.2.1295  0.6
2005 Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. The Journal of Clinical Investigation. 115: 711-7. PMID 15696194 DOI: 10.1172/JCI22982  0.6
2005 Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine (Berlin, Germany). 83: 193-202. PMID 15630593 DOI: 10.1007/s00109-004-0617-1  0.6
2004 Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proceedings of the National Academy of Sciences of the United States of America. 101: 14198-203. PMID 15375218 DOI: 10.1073/pnas.0406138101  0.6
2004 Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. The Journal of Clinical Investigation. 113: 694-700. PMID 14991067 DOI: 10.1172/JCI19210  0.6
2003 Sun Y, Subudhi SK, Fu YX. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends in Molecular Medicine. 9: 483-9. PMID 14604826 DOI: 10.1016/j.molmed.2003.09.011  0.6
2003 Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 171: 3348-52. PMID 14500627  0.6
2002 Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine. 8: 1405-13. PMID 12426559 DOI: 10.1038/nm796  0.6
2002 Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. Journal of Immunology (Baltimore, Md. : 1950). 168: 4480-7. PMID 11970992  0.6
2002 Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 168: 1457-65. PMID 11801689  0.6
2000 Cassel DL, Subudhi SK, Surrey S, McKenzie SE. GATA and NF-Y participate in transcriptional regulation of FcγRIIA in megakaryocytic cells Blood Cells, Molecules, and Diseases. 26: 587-597. PMID 11112392 DOI: 10.1006/bcmd.2000.0337  0.6
Show low-probability matches.